CI
RPRX

Cowen Inc’s Repros Therapeutics Inc. RPRX Stock Holding History

Cowen Inc’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-24,400
Closed -$654K – 335
2013
Q3 		$654K Buy
+24,400
New +$523K 0.1% 126

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
CC
CQS Cayman Camana Bay, Grand Cayman, Cayman Islands $2.26B AUM 1.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cowen Inc's RPRX Position: Q4 2013 in Review

Cowen Inc sold out of Repros Therapeutics Inc. (RPRX) in Q4 2013, closing a stake of 21,900 shares — an estimated $587K sold.

Cowen Inc first reported a position in RPRX in Q3 2013 and held it in 1 quarter. The position peaked at $587K in Q3 2013. 79 funds tracked by Wall St. Rank hold RPRX as of Q4 2013.

  • Cowen Inc reported no remaining Repros Therapeutics Inc. position as of Q4 2013 after selling out during the quarter.
  • Cowen Inc sold 21,900 Repros Therapeutics Inc. shares in Q4 2013, an estimated $587K.
  • Cowen Inc first reported a position in Repros Therapeutics Inc. in Q3 2013 and held it in 1 quarter.
  • Cowen Inc's Repros Therapeutics Inc. position peaked at $587K in Q3 2013.
  • 79 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q4 2013.

Based on Cowen Inc's 13F filing for Q4 2013, filed 13 Feb 2014.